Drug Patents owned by Currax

1. List of Onzetra Xsail drug patents

ONZETRA XSAIL's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8047202 CURRAX Nasal devices
Jul, 2023

(2 months from now)

US8327844 CURRAX Nasal delivery method
Oct, 2023

(6 months from now)

US9119932 CURRAX Nasal delivery device
Apr, 2024

(1 year, 21 days from now)

US7975690 CURRAX Nasal devices
Aug, 2025

(2 years from now)

US8590530 CURRAX Nasal delivery devices
Sep, 2025

(2 years from now)

US9108015 CURRAX Nasal delivery devices
Sep, 2025

(2 years from now)

US10124132 CURRAX Nasal delivery
Mar, 2027

(3 years from now)

US10398859 CURRAX Nasal delivery devices
Dec, 2027

(4 years from now)

US8875704 CURRAX Nasal administration
Apr, 2028

(5 years from now)

US10722667 CURRAX Nasal administration
Dec, 2028

(5 years from now)

US10076615 CURRAX Nasal delivery
Jul, 2029

(6 years from now)

US8550073 CURRAX Nasal delivery
Oct, 2029

(6 years from now)

US8899229 CURRAX Powder delivery devices
Aug, 2030

(7 years from now)

US9649456 CURRAX Nasal administration
Oct, 2030

(7 years from now)

US8978647 CURRAX Nasal delivery
Dec, 2030

(7 years from now)

US10478574 CURRAX Nasal administration
Nov, 2033

(10 years from now)

US10076614 CURRAX Nasal delivery devices
Oct, 2034

(11 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: Method of drug delivery via the nasal cavity; Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; Acute treatment of migraine; T...

Dosage: POWDER;NASAL

More Information on Dosage

ONZETRA XSAIL family patents

67

United States

39

United Kingdom

26

European Union

19

Japan

16

Australia

12

Canada

11

Spain

11

China

IB

10

IB

8

Denmark

8

Poland

6

Austria

6

Korea, Republic of

6

New Zealand

5

Mexico

5

Russia

5

Germany

4

South Africa

4

Brazil

3

Hong Kong

3

Singapore

2

Slovenia

2

Norway

2

Portugal

2

India

1

Israel

1

Turkey

1

Cyprus

1

Indonesia

1

Malaysia

2. List of Silenor drug patents

SILENOR Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238620 CURRAX Methods of using low-dose doxepin for the improvement of sleep
May, 2027

(4 years from now)

US10653662 CURRAX Methods of using low-dose doxepin for the improvement of sleep
May, 2027

(4 years from now)

US9486437 CURRAX Methods of using low-dose doxepin for the improvement of sleep
May, 2027

(4 years from now)

US9861607 CURRAX Methods of using low-dose doxepin for the improvement of sleep
May, 2027

(4 years from now)

US9572814 CURRAX Methods of improving the pharmacokinetics of doxepin
Jul, 2027

(4 years from now)

US10653660 CURRAX Methods of improving the pharmacokinetics of doxepin
Jul, 2027

(4 years from now)

US11110074 CURRAX Methods of improving the pharmacokinetics of doxepin
Jul, 2027

(4 years from now)

US7915307 CURRAX Methods of improving the pharmacokinetics of doxepin
Aug, 2027

(4 years from now)

US11234954 CURRAX Low-dose doxepin for treatment of sleep disorders in elderly patients
Jan, 2028

(4 years from now)

US10548871 CURRAX Low-dose doxepin formulations and methods of making and using the same
Apr, 2028

(5 years from now)

US9907780 CURRAX Low-dose doxepin formulations and methods of making and using the same
Apr, 2028

(5 years from now)

US11096920 CURRAX Low-dose doxepin formulations and methods of making and using the same
Apr, 2028

(5 years from now)

US9107898 CURRAX Methods of using low-dose doxepin for the improvement of sleep
May, 2028

(5 years from now)

US9532971 CURRAX Low-dose doxepin formulations and methods of making and using the same
Jun, 2029

(6 years from now)

US8513299 CURRAX Methods of using low-dose doxepin for the improvement of sleep
Sep, 2030

(7 years from now)

Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient

Market Authorisation Date: 17 March, 2010

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

How can I launch a generic of SILENOR before it's patent expiration?
More Information on Dosage

SILENOR family patents

54

United States

5

Japan

4

Canada

2

European Union

3. List of Treximet drug patents

TREXIMET Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7332183 CURRAX Multilayer dosage forms containing NSAIDs and triptans
Oct, 2025

(2 years from now)

US7332183

(Pediatric)

CURRAX Multilayer dosage forms containing NSAIDs and triptans
Apr, 2026

(3 years from now)

Drugs and Companies using NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 15 April, 2008

Treatment: Treatment of migraine; Acute treatment of migraine

Dosage: TABLET;ORAL

How can I launch a generic of TREXIMET before it's patent expiration?
More Information on Dosage

TREXIMET family patents

3

United States

2

Norway

1

Israel

1

Lithuania

1

Japan

1

Hungary

1

Slovenia

1

Portugal

1

Denmark

1

Cyprus

1

Austria

1

Canada

1

Spain

1

Mexico

1

Australia

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic